Skip to main content
Premium Trial:

Request an Annual Quote

Pangene Announces Launch of Genomics Web Portal Service

NEW YORK, May 17 – Pangene, a Fremont, Calif. pharmaceutical and genomics services company, announced on Monday the launch of DirectGenomics, its genomics web portal for cloning and gene expression screening. 

Customers can use the web portal to supply gene sequence information to Pangene. The company then uses this information to produce full-length cDNA gene clones that it delivers to the customer via Federal Express, the company said. 

Pangene,which focuses on developing drugs for DNA repair enzymes that are dysregulated in tumors, developed the services available on the website for its in-house drug validation, said Heather Butler, a Pangene technical sales associate. In 1999 the company decided to make the gene cloning services available to customers on a fee basis. The recently launched website adds gene expression screening to the previously available cloning options and allows customers to maneuver through the system and track orders via the web, said Butler. 

The web services business is aimed at biotech, pharmaceutical, and academic customers. It was created as a separate revenue stream from Pangene’s drug development efforts, said Butler. 

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.